Fellow joins team in winning prize for innovative ovarian cancer test
04 Oct 2017
NRN AEM fellow, Dr Sofia Teixeira, is part of the team of researchers from Swansea University who won an international award for a graphene biosensor based diagnostic test for ovarian cancer which is quicker, more accurate, less expensive and portable.
Dr Sofia Teixeira whose research in to graphene, semi-conductors based sensors has, along with her research colleagues, won the i3S Hovine Capital Health Innovation prize, created this year, aimed at distinguishing innovative ideas in the area of health.
The team from Swansea University, led by Professor Steven Conlan, have developed a devise which can diagnose the early stages of ovarian cancer. The developed testing device can diagnose the cancer in a few minutes using a drop of blood. This portable technology is different from the ones currently in the hospital environment and allows for greater flexibility in terms of monitoring a patient even after she has already been diagnosed with ovarian cancer.
The NRN, as a pan Wales initiative, promotes innovative use of materials and flexible research programs with influence form major Welsh universities. Together with the freedom to engage with industry partners and overseas collaborators, NRN funding has given Dr Teixeira a base to explore multidisciplinary research which has aided in the basis for this breakthrough diagnostic test.
"Being part of the network has enabled me to develop fundamental materials based challenges alongside translational clinical research, with a deeper understanding of process engineering and clinical need.
The award of the i3S Hovine Capital Health Innovation prize is an excellent example of this, based on close collaborations in Wales (Swansea University and ABMUHB) and Portugal (INL) to develop a testing device that can diagnose ovarian cancer in a few minutes using a drop of blood. We aim to overcome sensitivity and selectivity hurdles experienced with current diagnostic techniques using advanced engineering platform that interface with novel biomarker detection.
As well as the test being simple and fast the test does not require a technically-developed laboratory or a specialized technician to operate it which reduces costs and means that there isn’t a need for a centralisation of services. Excitingly, the platform is flexible and can be adapted for use in other pathologies and disease presentations based on panel biomarkers."
"...providing the base for an open research environment with access to multiple collaborating institutes, the NRN provides an excellent base for flexible thinking. With the support from home institution and the wider network, NRN really has provided me with opportunities that would not be afforded through single institute fellowships."
- Dr Sofia Teixeira
Ovarian Cancer News Today
An international research team at Swansea University Medical School and the university’s Centre for NanoHealth in the United Kingdom has received an international award for developing a graphene biosensor-based diagnostic test for ovarian cancer that offers quicker and more accurate results in a less expensive and portable way.
An international team of researchers led by Professor Steven Conlan, Swansea University Medical School and the Centre for NanoHealth has won an international award for a graphene biosensor based diagnostic test for ovarian cancer which is quicker, more accurate, less expensive and portable.